Dompe' Farmaceutici S.p.a.

Advanced Accelerator Applications Sa

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori

Dompe Pha.r.ma S.p.a.

Fondazione Irccs Istituto Nazionale Dei Tumori

Vito Di Cioccio

Marcello Allegretti

Carmelo A Gandolfi

Gianfranco Caselli

Maria Candida Cesta

Riccardo Bertini

Cinzia Bizzarri

Valerio Berdini

Francesco Colotta

Mariangela Figini

Silvana Canevari

Franck Martin

Arrigo Aldo Gandolfi, Legal Representative

Maria Carla Gandolfi, Legal Representative

Giulio Agostino Gandolfi, Legal Representative

Janete Peloia Barroso Gandolfi, Legal Representative

Fracesco Colotta

Giovanni Maurizi

Margherita Cattozzo

(R)-2-Arylpropionamide compounds of formula (I), pharmaceutical preparations of the compounds and a process for making the compounds are described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonuclear leukocytes and monocytes at inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use as inhibitors of chemotaxis of neutrophils and monocytes induced by the C5a fraction of complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of polymorphonuclear leukocytes.

Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells

Antibody or fragment thereof, which specifically binds to folate receptor-alpha (FR&#x3b1;), wherein said antibody or fragment thereof comprises a light chain whose variable region comprises at least one of the following amino acid sequences: &#x2014;RASESVSFLGINLIH (SEQ ID NO: 3), &#x2014;QASNKDT (SEQ ID NO: 4), &#x2014;LQSKNFPPYT (SEQ ID NO: 5), and wherein the constant region of said light chain is a kappa constant region.

Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

(R)-2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear leukocytes (leukocytes PMN) and of monocytes at the inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use in the inhibition of the chemotaxis of neutrophils and monocytes induced by the C5a fraction of the complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of PMN leukocytes. The compounds of the invention are used in the treatment of psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion.

Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells

Growing community of inventors

L'Aquila, Italy

Vito Di Cioccio